Physician profile
Hui Hing Tin
NPI 1629261722
$6,982.61
in general payments reported to CMS, 2019-2025
18 companies · $1,966 in 2025
The $1,966 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.25 · 2021: $358 · 2022: $1,042 · 2023: $1,075 · 2024: $2,520 · 2025: $1,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,560.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,977.20 | 2021-2025 | Linzess, Creon, Rinvoq |
| Gilead Sciences, INC. | $1,419.63 | 2019-2025 | Vemlidy |
| Phathom Pharmaceuticals, INC. | $407.37 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $352.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $345.19 | 2023-2025 | Sucraid, Sucraid |
| Ibsa Pharma INC. | $244.85 | 2024 | Licart |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.22 | 2021-2024 | Xifaxan |
| Ardelyx, INC. | $233.86 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $187.08 | 2023-2025 | Linzess |
| Boston Scientific Corporation | $140.58 | 2025 | Bulkamid |
| Merck Sharp & Dohme LLC | $94.10 | 2023-2024 | Dificid |
| Pfizer INC. | $70.53 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $67.45 | 2024 | |
| Exact Sciences Corporation | $64.83 | 2023-2025 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $56.45 | 2021-2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $36.93 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $23.24 | 2025 | Bylvay |
| Novo Nordisk INC | $18.19 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hui Hing Tin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.